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Lung cancer still represents one of the most relevant health
problems in Western countries, being the most common cause
of cancer-related death. Small cell lung cancer (SCLC)
accounts for 25% of all lung cancers (Landis et al, 1998). The
majority of SCLC patients already have extensive disease at
diagnosis. 
In spite of more than two decades of intensive investigation
with various chemotherapy combinations, the prognosis of these
patients remains very poor, the median survival time still being
shorter than one year, and the probability of remaining alive after 5
years being remote (Johnson et al, 1990). 
Recently, several new agents have demonstrated activity against
SCLC. 
Topotecan is a semisynthetic hydrophilic analogue of campto-
thecin, an alkaloid derived from the oriental tree Camptotheca
acuminata. It exerts its cytotoxic effects through the inhibition of
the nuclear enzyme topoisomerase I (Chen and Liu, 1994). Single-
agent topotecan, administered as a short-term infusion daily ´ 5
days every 3 weeks, has produced remarkable results in either
chemo-naive or pretreated SCLC patients (Schiller et al, 1996;
Ardizzoni et al, 1997). Although this schedule has been the most
commonly used in phase II trials, other schedules like the 24-hour
infusion weekly administration, the 21-day low-dose continuous
infusion etc. have been testing in the last few years, giving inter-
esting results (Slichenmeyer et al, 1993; Burris et al, 1994; Haas
et al, 1994; Hochster et al, 1994). 
Paclitaxel has also been tested as single agent in SCLC patients.
In two phase II studies it produced an ORR of 34% and 41% in
unpretreated patients with extensive disease (Kirshling et al, 1994;
Ettinger et al, 1995). It has also been tested in combination with
cisplatin (or carboplatin) and etoposide with promising prelimi-
nary results (Levitan et al, 1995; Kelly et al, 1996; Hainsworth
et al, 1997; Glisson et al, 1999). 
It has recently been reported that the weekly short-term (1- or 3-
hour) administration of paclitaxel may result in a dramatic increase
of the dose-density, at a price of a moderate toxicity (Fennelly et al,
1997; Akerley et al, 1998; Sikov et al, 1998). 
The combination of topotecan and paclitaxel was tested in
chemo-naive SCLC patients, showing a very promising ORR and
median survival. However, haematologic toxicity proved to be
relevant, and prolonged G-CSF support was required (Jett et al.,
1997). 
In view of the relevant myelotoxicity associated with both
the topotecan-cisplatin (Rowinsky et al, 1997) and topot-
ecan–paclitaxel combinations (O’Reilly et al, 1997) when the
standard 5-day topotecan administration is used, we previously
conducted a phase I study testing the simultaneous weekly admin-
istration of cisplatin, paclitaxel and topotecan (CPT). In the pres-
ence of G-CSF support from days 3 to 5 of each week, doses of
cisplatin 40 mg/m2, paclitaxel 85 mg/m2 and topotecan 2.25 mg/
m2 were given weekly at a price of mild haematologic and nonhae-
matologic toxicity (Frasci et al, 1999). 
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Summary The present study was aimed at defining the antitumour activity of the cisplatin-paclitaxel-topotecan (CPT) weekly administration
with G-CSF support in chemo-naive SCLC patients with extensive disease (ED-SCLC). Chemonaive ED-SCLC patients received cisplatin
40 mg/m2, paclitaxel 85 mg/m2, and topotecan 2.25 mg/m2 weekly, with G-CSF (5 mg/kg days 3–5) support, for a maximum of 12 weeks.
37 patients were treated, for a total of 348 cycles delivered. 8 complete responses (22%) and 22 partial responses (59%) were recorded,
giving an 81% [95% CI = 65–92%] ORR. At a 13-month (range, 4–26) median follow-up, median progression-free and overall survival were 8
months and 12.5 months, with 1-year and 2-year projected survivals of 55% and 21%, respectively. No toxic deaths occurred. Grade 4
neutropenia and thrombocytopenia occurred in 6 and 3 patients, respectively. Only one case of neutropenic sepsis was recorded, while
haemorrhagic thrombocytopenia was never observed. Diarrhoea, paraesthesias and fatigue were the main nonhaematologic toxicities being
severe in 6, 2 and 10 patients, respectively. The weekly CPT combination with G-CSF support represents a well tolerated therapeutic
approach in chemo-naive ED-SCLC patients. The activity rate seems at least similar to that achievable with the standard front-line
approaches. © 2001 Cancer Research Campaign http://www.bjcancer.com
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In view of the promising therapeutic activity observed in the
phase I study in both chemo-naive and pretreated SCLC patients,
we have undertaken this phase II study aimed at better defining the
efficacy of this new regimen as a front-line approach in patients
with extensive-disease small cell lung cancer. 
METHODS 
Eligibility criteria 
Candidates for this study were patients with histologically/cyto-
logically proven SCLC who had not received prior chemotherapy
or radiotherapy. Disease had to extend beyond the hemithorax of
origin and regional lymph-nodes. Other eligibility criteria
included clinically or radiologically measurable or evaluable
disease, age between 18 and 75 years, Zubrod performance status
of 0 to 2, life expectancy of at least 12 weeks, no previous or
concurrent malignancy, except for inactive non-melanoma skin
cancer, and in situ carcinoma of the cervix. 
Adequate bone marrow (absolute neutrophil count >2 ´ 109/l,
platelet count >100 ´ 109/l, and haemoglobin level >10 g l–1), liver
(bilirubin level <2 times the upper normal limit, AST and/or ALT
<3 times the upper normal limit, prothrombin time <1.5 times
control), and renal function (creatinine clearance >60 ml min–1)
were also required. The presence of severe cardiac arrhythmia or
heart failure, second- or third-degree heart block or acute myocar-
dial infarction within 4 months prior to study entry were consid-
ered as exclusion criteria. CNS metastases were not considered an
exclusion criterion, provided that a good symptomatic control
could be achieved with steroids. All patients gave their witnessed
written informed consent, and the protocol was approved by the
Ethical Committee for the Biologic Research of the National
Tumor Institute of Naples. 
Pretreatment workup 
Pretreatment evaluation included a complete history and physical
examination, determination of haematology, chemistry, and
tumour marker levels (CEA, TPA, NSE), ECG, chest X-ray, brain,
chest and abdomen CT, radionuclide scan of bone and broncho-
scopy. Additional radiologic examinations were also performed
as necessary to document the extent of disease. 
Treatment 
All eligible patients received paclitaxel 85 mg/m2 (as a 1-hour
infusion) followed by cisplatin 40 mg/m2 and topotecan 2.25 mg/
m2 as a 30-min i.v. infusion, weekly. Prophylaxis for hypersensi-
tivity reactions consisted of dexamethasone 8 mg i.v. 1 hour and
promethazine 50 mg i.v. plus ranitidine 50 mg i.v. 30 minutes
before paclitaxel administration. G-CSF was given at the dose of
5 mg/kg–1 day–1 days 3–5 of each week. A minimum of 6 treatment
administrations were delivered. Patients showing a clinical
complete or partial response received additional 6 administrations.
In absence of a major tumour regression patients were shifted to a
cyclophosphamide-doxorubicin-etoposide treatment. This regimen
was also used for patients relapsing after initial response. 
Patients with brain metastasis who developed progressive disease
at any time, or did not have a major response in the brain after 6
administrations, received whole brain radiotherapy. In patients who
had a major response in the brain after 6 administrations, whole
brain radiotherapy was deferred until after the 12th administration. 
Adjustments according to toxicity 
Chemotherapy was given at full doses if neutrophil count was
³1500/mm2, and platelet count ³100 000/mm2. For neutrophil
count >1000/mm2, or platelet count >75 000/mm2, it was
delivered at 50% of the planned dose. For neutrophil count
<1000/mm2, or platelet count <75 000/mm2 chemotherapy was
always omitted on that day. In presence of grade 4 neutropenia
lasting more than 7 days, febrile neutropenia (>38.5˚C with ANC
<500), grade 4 thrombocytopenia (lasting longer than 4 days),
grade 4 anaemia, grade 3–4 nonhaematologic toxicity (except for
nausea/vomiting and alopecia) the weekly chemotherapy dose
was reduced to 75% in the subsequent administrations. Dose
reduction was not performed for shorter than 4 days severe
myelosuppression. 
Toxicity and response assessment 
Toxicities and response were graded according to the WHO
criteria (Miller et al, 1981). 
Haematologic toxicity was assessed by performing weekly blood
cell count and differential. In cases of grade 4 haematological
toxicity occurrence these tests were performed every other day. 
For each patient, the worst toxicity encountered during the
treatment was reported. 
The clinical restaging was performed after 6- and 12-weekly
administrations. It consisted of physical examination, routine
laboratory tests, serum tumour markers, and repetition of all
initially abnormal diagnostic procedures. For bone metastases, the
standard WHO response criteria were applied: CR was considered
as the complete disappearance of all lesions on X-ray or scan for at
least 4 weeks; PR was defined as a greater than 50% reduction in
the number of the areas of uptake from the pretreatment radionu-
clide scan, or partial decrease (>50%) in size of lytic lesions, recal-
cification of lytic lesions, or decreased density of blastic lesions
for at least 4 weeks. 
All eligible patients were included in the response and survival
analysis, on an ‘intent to treat’ basis. Duration of complete
response was calculated from the date of the first documentation
of CR until date of disease progression; duration of partial
response, and time to treatment failure were both calculated from
the day of initial treatment until PD was firstly noted. Overall
survival (OS) was calculated from the beginning of treatment to
death by any cause. 
For time-to-event data, the cumulative proportion of patients
who had not yet experienced the event was plotted as function of
time by means of the Kaplan–Meier product-limit approach
(Kaplan and Meier, 1958). 
Study design 
Since we believe that the achievement of a complete response
often translates in a prolongation of survival in SCLC patients, we
have chosen the cCR rate as the main end-point of this study. 
We aimed at obtaining a 30% cCR rate with this new combina-
tion, and set a cCR rate of 10% as the lowest level of interest.
According to the Simon two-stage minimax design (Simon, 1989),
at least 7 complete responses were required among 33 patients toconsider this combination worth of further evaluation (alpha =
0.05; 1-beta = 90%). A first analysis was planned after 22 patients
had been enrolled. The accrual would have been stopped if fewer
than 3 complete responses had been observed. 
RESULTS 
Demographics 
Between August 1997 and July 1999 3 patients entered the study. 
Table 1 outlines the main patient characteristics. 29 patients
were male. Median age was 51 (range, 38–76) years, and 14
patients (38%) had a Zubrod performance status of 2. Clinically
asymptomatic brain involvement was present in 10 (27%) patients,
and 23 (62%) patients had increased LDH serum levels. 22 (59%)
patients had 3 or more sites of involvement. 
Response 
All the 37 enrolled patients were evaluated for response on an 
‘intent to treat’ basis. 
33 patients completed at least 6 administrations and were
assessed for response. 4 patients did not complete the first 6
administrations due to disease progression (2 cases), protracted
thrombocytopenia (1 case), or refusal (1 case). All of them were
considered as failures. 
An overall, 8 complete (22%) and 22 partial responses (59%)
were recorded, for a 81% [95% CI = 65–92%] overall response
rate (Table 2). All the 8 complete responses occurred in the first 33
enrolled patients. 6 complete responses were achieved after 6
administrations. In another 2 patients residual tumour persisted in
lung and liver after 6 cycles, but disappeared by the 12th adminis-
tration. Liver was the main site of disease involvement in 5/8
complete responders, the tumour being localized in bone (2) and
adrenal (1) in the remaining 3 cases. 
26 out of 30 responder patients received the planned 12 admin-
istrations of chemotherapy. In 3 patients chemotherapy was
suspended because of the occurrence of severe fatigue (2), or
peripheral neuropathy (1), while another patient refused treatment
after 8 administrations. 
7 of the 10 patients with brain metastasis achieved a major
response after 6 cycles. In 5 of these cases a major tumour regres-
sion was also observed in the brain, but it was never complete. 
Of the 14 patients with poor performance status, overall 6 major
responses (43%) were recorded, only one being complete. 
Survival 
At the time of the present analysis 5 patients were still progres-
sion-free and 11 were still alive, with a median follow-up time of
13 (range, 4–26) months in the survivors. Actuarial estimation of
median failure-free and overall survival for the entire population
was 8 months [95% CI = 6–9] and 12.5 months [95% CI = 8–14],
the 1-and 2-year survival rates were 55% and 21%, respectively
(Figures 1 and 2). The one-year survival probability was 68%,
61% and 29% in complete responders, partial responders, and
nonresponders, respectively. Among the 8 patients still alive at a
>18-month follow-up, 4 had achieved a complete response, and 3
a partial response, while the last one had failed to respond either to
first-line or second-line treatment. The 14 patients with Zubrod
performance status 2 experienced a substantially shorter median
survival time (8 months) than those with better performance status
(14 months). A worse survival outcome was also seen in the 23
patients with increased LDH serum levels at diagnosis. Indeed,
median survival was 7.5 months in this group, as compared to 14
months in the others. The median survival time was slightly
shorter in the 10 patients with brain metastasis (10 months) as
compared to the others (13 months). 
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Table 1 Patient characteristics 
Characteristic No. of patients 
Age, years 
Median 51 
Range 38–76 
Sex 
Male 29 
Female 8 
ECOG performance status 
06  
1 17 
2 14 
Site of metastasis 
Contralateral lung 21 
Extrathoracic lymph-nodes 4 
Liver 26 
Brain 10 
Bone 24 
Adrenal 8 
No. of disease sites 
1–2 15 
³3 22 
LDH serum levels 
Normal 14 
Increased 23 
Total 37 
Table 2 Responses (37 assessable patients) 
No. of patients 
Complete responses (%) 8 (22) 
Partial responses (%) 22 (59) 
Stable disease (%) 2 (5.5) 
Progressions (%) or treatment failures 5 (13.5) 
Overall responses (%) 30 (81) 
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Figure 1 Progression-free survival. Total patients = 37; progression-free = 5 Weekly cisplatin-topotecan-paclitaxel in SCLC 1169
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Toxicity 
Table 3 summarizes the myelotoxicity data on the overall 348
administrations. 
No toxic deaths were observed. Only one case of neutropenic
fever was recorded, after 9 chemotherapy administrations, in a
patient with massive liver and bone involvement. Overall, grade 3
and 4 neutropenia occurred in 10 (27%) and 6 (16%) patients,
respectively. Thrombocytopenia was less relevant, being of grade
3 in 7 patients (19%), while grade 4 never occurred. However, in
one patient (with a concomitant chronic hepatitis) a persistent
grade 3 thrombocytopenia occurred after 2 administrations, which
caused the definitive suspension of chemotherapy. Anaemia was
quite frequent especially in patients who received more than 6
administrations. Haemoglobin levels fell below 11 g l–1 in all
patients, and in 7 patients (19%) a packed red blood cell transfu-
sion was required. 
Alopecia was very frequent, occurring in 33 of the 37 enrolled
patients. Other nonhaematologic toxicities were generally mild/
moderate. Severe hypersensitivity reactions to paclitaxel were not
observed. Gastrointestinal toxicity was moderate in the majority of
patients and never led to definitive treatment discontinuation.
Grade 3 vomiting and diarrhoea occurred in 4 patients (11%) and 7
patients (19%), respectively. 
A 25% reduction of all 3 drug doses was performed in patients
showing severe diarrhoea and this prevented a further occurrence
of this side effect. 
Severe constipation was observed in 6 patients, and an ad-
ditional 3 patients had moderate transient elevation of hepatic
enzymes. Severe fatigue occurred in 10 patients, and in 2 cases it
led to the definitive suspension of the treatment (both patients
were responsive after the first 6 chemotherapy cycles). Neurologic
toxicity was not a problem in the majority of patients. Mild periph-
eral paraesthesia occurred in 12 patients (32%) and in an addi-
tional 4 patients (11%) a grade 2 neurotoxicity was observed. Only
2 patients showed grade 3 peripheral neuropathy: in one case it
occurred after 8 cycles, causing the discontinuation of chemo-
therapy, the other patient showed a worsening of peripheral
neuropathy after the completion of treatment. In both cases neuro-
toxicity persisted for several months. 
Musculoskeletal symptoms like transient arthralgia and myalgia
were quite frequent, occurring in an overall 19 patients (51%) but
they were never severe, and responded well to anti-inflammatory
drugs. 
Nephrotoxicity was almost non-existent: only 4 cycles were
associated with a mild and transient elevation of creatinine serum
level. 
Mucositis was not uncommon, but it was never severe. One or
more episodes of rhinorrhagia occurred in 13 patients. 
DISCUSSION 
The haematologic data of the present study confirms the findings
of our previous phase I trial testing this new weekly combination
(Frasci et al, 1999). Indeed, the occurrence of severe neutropenia
or thrombocytopenia was negligible with this combination, while
anaemia, although more frequent, actually cannot be considered as
a life-threatening toxicity. Severe nonhaematologic toxicity was
also uncommon. Gastrointestinal and neurologic side effects were
frequent, but rarely compromised the continuation of the treat-
ment. 
In view of the high chemosensitivity of SCLC, we did not
consider the rate of objective responses as a reliable parameter to
evaluate the capability of this new regimen to improve the prog-
nosis of SCLC patients. Indeed, ORRs higher than 80% have also
been reported in the past with the use of standard combinations not
including new agents (Johnson et al, 1990). 
In order to ascertain whether our new combination could be a
real step ahead in the treatment of SCLC patients, we set a quite
restrictive criterion to pursue in future phase III trials. Indeed, we
set a 30% complete response rate as the target activity rate, and
considered a complete response rate with a 95% confidence
interval which fell below 10% as uninteresting. 
A high proportion of patients has shown a major regression of
the tumour in the present trial, and the number of complete
responses observed (8), although not very impressive, exceeded
the minimum required by the study design. Moreover, it deserves
to be remarked that all patients showed disseminated disease at
beginning of chemotherapy. 
The short duration of the treatment could have had a role in
determining this unimpressive complete response rate. 
The presence of poor prognostic features at beginning of treat-
ment like poor performance status, brain metastases, and elevated
LDH serum levels could also have had a substantial role in under-
estimating the CR rate. Indeed, about 30% of patients treated by us
had brain metastasis, and none obtained a complete regression of
the tumour in the brain. The relevant number of patients with poor
performance status could also have contributed to reducing the
ORR and the CR rate of the whole population, since they were
43% and 7% in this group. 
The survival outcome of our patients deserves some additional
comments. Of course the absence of a randomization makes it
Table 3 Worst acute toxicity (37 patients) 
Toxicity WHO grade 
12 34  
Haemoglobin 13 17 6 1 
ANC 6 15 10 6 
Platelets 15 12 7 0 
Vomiting 20 11 4 0 
Diarrhoea 8 9 6 0 
Neuropathy 12 4 2 0 
Mucositis 9 5 0 0 
Fatigue 15 9 10 0 
Alopecia 11 15 7 0 
0
25
50
75
100
P
e
r
c
e
n
t
 
p
r
o
b
a
b
i
l
i
t
y
0
37 Patients at risk
6
29
12
16
18
10
24
4
Months
Median 12.5 months
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difficult to draw definite conclusions on this issue; however, we
think that the median survival time observed in our study popula-
tion is interesting. Indeed, if we look at the previous experiences
conducted either with ‘old’ or with ‘new’ combinations, the
achievement of a longer than 1-year median survival time was very
uncommon in extensive-disease patients. Moreover, as previously
remarked, our study population was not at all a ‘good-prognosis’
one. In fact, the survival outcome looks much better in our study if
patients with poor performance status or with elevated LDH serum
levels are excluded from the analysis, in these cases the median
survival times are 14 months and 15 months, respectively. 
Although it is impossible, on the basis of our results, to
conclude that the addition to cisplatin of paclitaxel and topotecan
can substantially modify the life expectancy of ED-SCLC patients,
it must be remarked that also in other trials which tested the topot-
ecan-paclitaxel regimen a good median survival was seen, even
when an unimpressive ORR and CR rate were obtained (Jacobs
et al, 1999; Lynch et al, 1999; Tweedy et al, 1999). However, the
results of the recent CALGB 9430 phase II trial testing the pacli-
taxel–topotecan combination do not suggest an advantage to this
regimen compared to standard etoposide and platinum (Lynch
et al, 2000). 
The use of weekly rather than daily times 5 every 3 weeks topot-
ecan was a peculiarity of the present study. It is interesting to
remark that the cumulative 3-week dose of topotecan in our study
(6.75 mg/m2) was much higher than those reported in other trials
testing the topotecan in two-or three-drug regimens (O’Reilly et al,
1997; Rowinsky et al, 1997; Dunphy et al, 1998; Ten Bokkel
Huinink et al, 1998; Raefsky et al, 1999). Other phase II trials
testing the cisplatin–paclitaxel–topotecan regimen in SCLC
patients have not been conducted. However, in a phase 1 study
from the Netherlands the cisplatin–paclitaxel–topotecan triple
combination was also tested, by using the standard every 3-week
schedule for all 3 drugs. In presence of G-CSF support doses of
cisplatin and paclitaxel of 75 mg/m2 and 110 mg/m2 (24-hour)
were given, and the dose of TPT did not exceed 0.4 mg/m2 d 1–5
every 3 weeks (Ten Bokkel Huinink et al, 1998). Preliminary
phase I experiences in refractory solid tumours with the carbop-
latin–paclitaxel–topotecan combination have also been reported. A
standard daily times 3 or 5 every 3 weeks schedule had always
been performed. The recommended dose of TPT was 0.5 mg/m2/d
´ 5 days, or 0.75 mg/m2/d ´ 3 days, in both cases giving a cumula-
tive over 3-week dose less than half of that delivered by us
(Raefsky et al, 1999; Dunphy et al, 1998). Preliminary phase II
results of this regimen in small cell lung cancer have also been
recently reported. An 88% overall response rate was obtained in
patients with extensive disease, although patients with poor perfor-
mance status tolerated treatment poorly (Gray et al, 2000). 
The very good tolerance of weekly topotecan given in a short-
term infusion as single agent has been recently confirmed by the
preliminary data of a phase I study, although activity data were not
reported (Clark et al, 1999). Therefore, further confirmations of
the efficacy of this schedule are required. 
In conclusion, the results of the present phase II study suggest
that 2 new drugs like paclitaxel and topotecan can be safely
combined at full doses with cisplatin, by using a weekly schedule
with G-CSF support. This combination results in both a good ORR
and promising median survival time. Only a large phase III trial
will establish whether this dose-dense chemotherapy approach can
produce a substantial prognostic improvement in extensive-stage
SCLC patients. 
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